• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Briefs

Industry Briefs

May 13, 2019

Flag Real-World Evidence in IND Applications, Guidance Says

Sponsors that plan to use real-world evidence in drug development must identify the sources of that evidence when requesting an IND from the FDA.

IND cover letters should indicate whether a sponsor hopes to use real-world evidence to support the safety or efficacy of a drug, to change a drug’s label, or to comply with a postmarketing requirement, the agency says in a draft guidance released last week.

The guidance draws a line between real-world data — information about patients’ health status or healthcare delivery “routinely collected from a variety of sources,” including electronic health records, medical claims or billing data — and clinical evidence for a drug from analysis of real-world data.

Regulators only want to track real-world evidence that relate to specific products or regulatory decisions, so sponsors don’t have to flag natural histories used to establish a clinical outcome test or biomarker, feasibility studies involving real-world evidence or studies that use real-world data “to perform exploratory analyses and generate hypotheses,” the draft guidance states.

Read the draft guidance here: https://bit.ly/2LM1uPN.

FDA Releases Draft Guidance on Clinical Lactation

The FDA has published recommendations for drug sponsors planning trials that potentially will enroll breastfeeding women. The aim of the draft guidance issued last week is to protect the health and safety of research subjects and their babies.

The guidance specifies the circumstances that should lead sponsors to study the effects of a new investigational drug on lactation before enrolling women of reproductive age in a clinical trial. It also addresses approved drugs seeking a new indication that may be used by breastfeeding women.

Read the draft guidance here: https://bit.ly/2vR4AqB.

Nonprofit Healthcare System Plans Its First Gene Editing Trial

Christiana Care Health System’s Gene Editing Institute has announced plans for its first investigator-initiated trial, which will use genome editing to address late-stage lung cancer.

The nonprofit community medical system plans to use the CRISPR genome editing platform to develop a treatment for K-ras-positive non-small cell lung cancer patients in stages 3 and 4 of the disease.

Christiana’s Gene Editing Institute is collaborating with its Graham Cancer Center and Research Institute on the trial protocol and development of an IND submission to the FDA.

Elligo to Spend $20 Million on Patient-Trial Connection Database

Elligo Health Research last week announced it had raised $20 million to expand its program to connect physicians and their patients with clinical trials.

The Texas-based integrated research organization plans to extend its reach into more states and further develop its IntElligo Research Stack technology, which it uses to search electronic health records for study criteria like therapeutic specialty, patient pool demographics and office location and connect practices with upcoming clinical trial opportunities.

Sensei, AstraZeneca to Collaborate on Study of Combination Therapy

Sensei Biotherapeutics has announced a clinical trial collaboration with AstraZeneca to evaluate the safety, tolerability and preliminary activity of AstraZeneca’s IMFINZI (durvalumab) in combination with Sensei’s first-in-class immunotherapy candidate, SNS-301.

The companies will study the effect of the combination on patients with locally advanced head and neck cancer as well as patients with various locally advanced unresectable or metastatic/recurrent solid tumors.

AstraZeneca will supply IMFINZI and Sensei will sponsor and fund the Phase II studies. AstraZeneca and Sensei each will retain full worldwide rights to their respective molecules.

WuXi AppTec Adds Pharmapace to Clinical Portfolio

Shanghai-based WuXi AppTec will bolster its CRO arm, WuXi Clinical, with the acquisition of biometrics service provider Pharmapace, the company announced last week.

Taking advantage of China’s recent regulatory reforms allowing overseas trial data, WuXi plans to use Pharmapace’s services to expand its global reach and provide drug development solutions across the board.

C3J Therapeutics and AmpliPhi Biosciences form Armata Pharmaceuticals

Armata Pharmaceuticals, Inc., a new clinical-stage biotechnology company, has been created with the close of a merger between C3J Therapeutics, Inc., and AmpliPhi Biosciences Corporation.

The newly created company will concentrate on the development and advancement of phage-based therapeutic candidates to treat antibiotic-resistant infections.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing